BioVie Inc. announced that results from its Phase 2 trials of bezisterim, an investigational drug targeting neuroinflammation, will be presented at the 2026 American Neurological Association meeting. The trials include ADDRESS-LC for Long COVID and SUNRISE-PD for early Parkinson's disease. Bezisterim showed promise in improving inflammation markers and symptoms in Parkinson's patients and is being studied for neurological symptoms in Long COVID. These presentations mark a key step in advancing bezisterim's clinical development for neurological disorders.
BioVie and its bezisterim drug development are the focus here, with Pluang data providing market context. For readers following the Health sector, here is Pluang's snapshot as of Oct 14, 2026 19:01 WIB: Among 150 priced US Health stocks, 105 rose and 40 fell. Alcon AG (ALC) traded at USD 64.17 with a 1.86% gain and 100% buy order activity, contrasting with BioNano Genomics Inc (BNGO) at USD 1.39, up 1.84% but with 98% sell orders. AstraZeneca plc (AZN) stood at USD 158.67, up 1.83%, with a longer typical hold time of 127 days and a more balanced order split of 58% sell to 42% buy.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
